Share the QR code < / P > < p > with wechat scanning code to friends and circle of friends < / P > < p > after completing five rounds of centralized drug volume procurement, special volume procurement such as biological similar drugs and Chinese patent medicines will also be started. The reporter learned that the national organization's insulin belt procurement is about to start, which is the first biological similar drug included in the national belt procurement in China. At the same time, the volume procurement of Chinese patent medicine has also been put on the agenda. The National Medical Insurance Bureau recently revealed that it will scientifically and steadily promote the centralized procurement reform of Chinese patent medicine and formula granules < p > < / P > < p > insulin belt procurement is about to start < / P > < p > after nearly a year of brewing, the special insulin belt procurement will be officially launched. According to an insider, on August 18, the price bidding and procurement department of the National Medical Insurance Bureau issued the national organization insulin centralized belt procurement plan (Exposure Draft), proposing that after soliciting the opinions of relevant departments, various regions across the country will be organized to form an alliance in September to carry out the national organization insulin belt procurement with public medical institutions as the implementation subject, and the procurement cycle is 2 years, The successful results will be implemented in early 2022

wind and cloud medicine, told reporters in an interview with the economic reference daily that the procurement of insulin band will reduce the cost of medication, gradually change the structure of medication for diabetes treatment, and further enhance the penetration of insulin. In addition, insulin is a subdivided field of biological products. The implementation of this volume procurement also demonstrates the centralized procurement of biological products, further expand the coverage of the national drug procurement policy and bring benefits to more patients < p > Zhang Tingjie predicted that according to the results of previous batches of belt procurement, the average decline was more than 50%, the average decline of Wuhan insulin belt procurement was also 43%, and the decline of national insulin belt procurement is expected to exceed 50% < p > although the price has decreased, from the perspective of the scheme, insulin medication will respect the clinic more. The plan points out that quality is the priority. We will adhere to starting from the clinic, respect the use choice of medical institutions, report the quantity to the general name (each brand), and the medical institutions will choose the quantity independently according to the needs and rules. Ensure that the results of centralized volume procurement are shared by the majority of patients and directly benefit the masses < p > "insulin procurement rules are different from chemical drugs." Zhang Tingjie said that this report is no longer based on the usage of the past year, but the expected usage of the next year. At the same time, different from the general name reporting volume of chemical drugs, insulin will adopt the general name plus brand reporting volume, giving medical institutions more choices < p > Li Zhixin, chief analyst of capital securities, also said that according to the complexity and long-term use of insulin products, the scheme clearly respects medication habits and highlights the autonomy of medical institutions in the reporting stage and component stage. In addition, ensure basic supply and encourage enterprises to exchange price for quantity at the same time

's market structure or reshaping of Sullivan, a consultant at

, showed that in 2018, the national diabetes drug market reached 52 billion 400 million yuan, of which insulin and its analogues ranked first, accounting for 46% yuan, accounting for 26 billion 400 million yuan. According to intranet data, in 2020, the sales of insulin and similar drugs at the terminals of public medical institutions in China were about 27 billion yuan, a year-on-year increase of 7.9% < p > demand will continue to grow. According to the International Diabetes Federation (IDF), in 2017, there were as many as 425 million people in the world with diabetes mellitus (20-79 years old) and 352 million patients with latent type 2 diabetes. It is estimated that by 2045, the number of diabetic patients in the world will reach 629 million, of which more than 150 million people are in China. p> < p > at present, foreign enterprises are still in a semi monopoly position in China's insulin market. According to the data of Zhongkang industrial capital research center, represented by the original drug manufacturers Novo Nordisk, Sanofi and Eli Lilly, the total market share in the first quarter of 2021 exceeded 77% < p > under this background, the market share of some pharmaceutical enterprises in China has great room for improvement. According to the data of Fengyun drug talk, in terms of the scale and proportion of major insulin participants in 2020, Novo Nordisk has a market share of 48% with a price of 7.07 billion yuan; Sanofi paid 2.79 billion yuan, accounting for 19%; The market scale of Ganli pharmaceutical industry is 1.97 billion yuan, accounting for 14%; Lilly's scale is 1.06 billion yuan, accounting for 7%; Tonghua Dongbao was 1.01 billion yuan, accounting for about 7% < p > "the purchase of insulin with quantity will promote the reshaping of the competitive pattern of the insulin industry and accelerate domestic substitution." Zhang Tingjie believes that China's Gan Li pharmaceutical, Tonghua Dongbao and UL have clear price advantages, and we can also see a significant increase in market share in recent years. In addition, the plan links the centralized procurement volume with the enterprise's production capacity. In order to ensure the supply, when the selected quantity of medical institutions exceeds 50% of the maximum production capacity of each enterprise in the domestic market, the medical institutions will no longer be open to choose the product, which has no material obstacles to the current domestic insulin enterprises such as Ganli pharmaceutical and Tonghua Dongbao < p > the scheme is clear. It will be divided into three categories: A, B and C according to the quotation level. All or part of the reported volume will be obtained according to the quotation level, while part of the reported volume of non winning enterprises will be allocated by medical institutions to qualified winning enterprises. For example, the first selected enterprise will receive 100% of the reported volume of the organization, 80% of the reported volume of other class A and B, and 50% of the reported volume of class C < p > an insider pointed out that the number of insulin winning enterprises will expand compared with chemical drugs, but the "price reduction" will still determine the future of the product. If the price reduction of the product fails to meet the expectations and is included in category C, it will not only not get the full amount, but also face the reality that the basic amount will be divided up. In the fully competitive insulin field, this increase and decrease will greatly increase the difficulty of the game, It obviously affects the bidding strategy of enterprises' volume purchase < p > it is expected to expand the range of varieties purchased in belt quantity < / P > < p > while the centralized belt quantity procurement channel of insulin is opened, the inclusion of Chinese patent medicine in belt quantity procurement is also accelerating < p > on August 9, the national medical insurance bureau pointed out in its reply to "suggestions on accelerating the integration of Chinese patent medicines and formula granules into centralized procurement", that it will work with relevant departments to improve the quality evaluation standards of Chinese patent medicines and formula granules, adhere to quality priority, take clinical demand as the guidance, and start with varieties with high price and large quantity, We will scientifically and steadily promote the reform of centralized procurement of Chinese patent medicines and formula granules < p > on August 17, Hubei Province officially launched the Centralized Procurement Alliance of Chinese patent medicine, and invited other provinces to form a "provincial cross regional alliance for the procurement of Chinese patent medicine". 17 groups of Chinese patent medicines are planned to be selected for this volume procurement, which are divided into oral and injection groups according to the route of administration, with a total of 74 varieties. The market scale is nearly 20 billion yuan, involving 292 enterprises < p > at the beginning of 2021, the general office of the State Council issued the notice on promoting centralized drug procurement with quantityAccording to the opinions on institutionalized development, in accordance with the principle of basic and clinical protection, focus on the drugs with large consumption and high purchase amount in the catalogue of basic medical insurance drugs into the scope of purchase, and gradually cover all kinds of clinically necessary and reliable drugs listed in China, so as to ensure that they should be adopted as much as possible < p > "it is an institutional requirement that large varieties of biological similar drugs, including Chinese patent drugs, be included in the procurement with quantity." Chen Jinfu, deputy director of the National Medical Insurance Bureau, previously said at a regular policy briefing held by the Information Office of the State Council that the volume procurement rules for biological similar drugs and Chinese patent drugs will be more optimized, targeted and the quality will be more in line with the attributes of the drug itself < p > Zhang Tingjie reminded that whether it is the centralized purchase of biological similar drugs or Chinese patent drugs, it is necessary to prevent the simple pursuit of substantial price reduction, resulting in the phenomenon of "bad money expelling good money". Enterprises should consider uncertain factors and reasonably estimate the corresponding space from the perspective of cost, so as to avoid the event that Huabei pharmaceutical ibuprofen sustained-release capsules were out of stock for many times before, and voluntarily proposed to give up the qualification of centralized procurement < p > (reporter Liang Qian) < / P > < p >